Crushed Q1, margins locked, but guidance sits tight

Delivered result confirms ₹1,940.5 Cr revenue, YoY +38.2%

Organic 19.6% – claimed – yields 580 bps excess to IPM. Consistent with 40% like-for-like growth less inorganic 20.4%

OPM 5.0% confirmed; management states 5% EBITDA margin achieved; matches guidance

Delivered PAT ₹52.1 Cr is +72.2% YoY; NPM 2.7% confirmed

Revenue +38.2%, EBITDA ~94% growth implies margin expansion occurred; consistent with 5% vs lower prior quarters

Management confirmed only small Sai Pharma surgical consumable deal in AP (immaterial). Inorganic 20.4% purely from prior year acquisitions

Management disclosed 2.5% revenue drag from conscious exits (sub-distribution, not hospital). Organic 19.6% implies 2.5% headwind absorbed

Management stated ROCE 11.5% → 21.1%, ROE 9% → 20.4%. Both ahead of FY26 full-year numbers

Management reaffirmed all three targets despite beating Q1. No guidance raise despite strong quarter

Management stated 'comfortably above ₹1,000 Cr for this full year' organically. On track confirmed

EBITDA margin expanded 143 bps to 5%, ahead of guidance, driven by MedTech contribution, scale procurement, deliberate low-margin exits

ROCE jumped 11.5% → 21.1% (950 bps), ROE 9% → 20.4% (1,140 bps), both ahead of FY26 full-year, reflecting capital efficiency improvement

Organic 19.6% beats IPM 13.8% by 580 bps YoY, larger than 200 bps prior. Market share capture accelerating without acquisitions

Shifted focus from inorganic (major M&A prior 2 years) to organic consolidation. No major acquisitions planned FY27; remain open only in Q4

FY27 23% growth, 5% EBITDA, 50% EBITDA-to-OCF all MAINTAINED despite Q1 beat. No raise despite strong quarter signals caution

Unique value proposition: 3,000 manufacturer relationships, 83,400 SKUs, pan-India reach. 2-way network moat. Excess growth from wallet share gains and new customer additions, not just IPM.

Q4 had one-off items that depressed margins. Removing those, Q4 was close to 5%. Aspiration is to improve further, but no specific Q-by-Q guidance given.

Roughly flat range. ₹200 Cr debt taken in Q4 for acquisition; Q1 sees full-quarter impact. Won't decline materially.

Government project/diagnostic PPP revenue was pulled forward into Q4 due to budget close-down. Part of Q1 revenues moved to Q4 in prior quarter.

Can't forecast. We can't isolate the specific reason for the acceleration. But our organic forecast was built on lower IPM assumption, so we're comfortable either way.

No, we'll stay with original guidance. Let's complete Q2, then revisit for second-half outlook.

Q4 had machines depreciated aggressively based on revenue yield. Q1 level is what you'll see going forward, subject to major capex.

2-5 year timeline per agreement. No defined path in contracts on funding source (parent vs subsidiary). Will choose based on optimization.

Primarily wallet share increase from customers. USP is fill rate, product availability, range, collaborations.

We participate in patented drugs, branded generic, trade generic (98-99% of Indian pharma). Not pure generic. So we benefit from mix shift.

Both segments create opportunity. MedTech has more Pan-India collaboration potential, demand-generation role (commercial), fewer competitors. Pharma is fulfillment-focused.

20% definitely achievable. Less competition in MedTech vs pharma. Opportunities for value-add more meaningful.

Primarily sub-distribution, not hospital. Opportunities exist but we first try to improve margins before letting go. Will renegotiate terms.

Wallet share contribution to growth > new customer contribution. New customers start with low wallet share; takes quarters to build it.

Balance sheet not audited quarterly. Disclosed semi-annually in Sept & March. OCF is annual metric due to seasonality (Q2 peak).

Why limit to 6%? Internal aspiration is >6% for sure. Cost base won't grow at 20%, so operating leverage + procurement benefits will drive expansion.

Yes, comfortably above ₹1,000 Cr for full year.

11-12% from acquisition calendarization, rest (~11-12%) organic.

Always targeting higher margins Q-on-Q. But FY27 guidance remains 5%. May update after Q2 if H1 signals higher.

No, not all in FY27. 2-5 year timeline per agreement.

Not product-driven. Role-driven. Demand generation (us + manufacturers) yields higher margin than fulfillment-only. MedTech has more demand-gen opportunity.

Wallet share = reflection of value proposition. We increase value (more companies, warehouses, better experience) → higher allocation from retailers.

Depends on subsidiary profit. Q4 had revenue preponement in one subsidiary, boosting their earnings share. Q1 more normalized.

Reaffirmed despite Q1 beat. Includes 11-12% from prior acquisition calendarization, ~11-12% organic. Conservative relative to Q1 38.2% (but Q1 inflated by inorganic 20.4% + one-offs)

Already achieved in Q1. No upside guidance provided despite beat. Aspiration >6% stated but not formalized. Sequential improvement targeted but not quantified

No capex guidance disclosed. Q1 depreciation normalized after Q4 one-off machine depreciation adjustments

Management acknowledged unable to isolate reason for IPM acceleration from 7-9% to double-digit. Historical cyclicality (10-12% → 7-9% → 10-12% over prior cycles) suggests reversion risk. Organic growth thesis depends on sustained 19%+ excess to IPM.

Q4 saw government project/diagnostic PPP revenue pulled forward due to budget close-down. Q1 benefited by reversal of this timing, boosting margins. Future quarters may lack this tailwind; run-rate margins may be lower than Q1's 5%.

Entero completed significant M&A over prior 2 years. FY27 shift to organic consolidation means integration execution critical. Failed synergy realization or culture clashes could derail return ratio targets (ROCE 25-30% over 3-4 years).

Generic drug participation increasing in Indian pharma (trade generic and pure generic growing). Entero participates in patented drugs, branded generic, trade generic (98-99% of pharma) but not pure generic. Risk of margin compression if trade-generic and pure-generic segment pricing deteriorates faster than Entero's pricing power.

Q1 inorganic growth (20.4%) driven by acquisition calendarization. Subsidiary profit concentration (NCI variability Q4 ₹17 Cr → Q1 ₹14 Cr) hints at earnings dependency. No detail on top customer concentration or top-5 subsidiary contribution.